



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/528,353	
			Filing Date	September 22, 2003	
			First Named Inventor	Nobuyuki Yasuda	
			Art Unit		
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	082368-003300US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	AK	HINKE, S.A. et al.; "Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1"; <u>Biochem. Biophys. Res. Commun.</u> ; March 15, 2002; pp. 1302-1308; vol. 291, No. 5		
	AL	HINKE, Simon A. et al.; "On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors"; <u>Diabetes Care</u> ; August 2002; pp. 1490-1491; Vol. 25, No. 8		
	AM	YAMAZAKI, Kazuto et al.; "The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight"; <u>European Journal of Pharmacology</u> ; 2004; pp. 213-218; Vol. 488		
	AN	YASUDA, N. et al.; "Enhanced secretion of glucagons-like peptide 1 by biguanide compounds"; <u>Biochem. Biophys. Res. Commun.</u> ; November 15, 2002; pp. 779-784; Vol. 298, No. 5.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60669516

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/528,353
Filing Date September 22, 2003
First Named Inventor Nobuyuki Yasuda
Art Unit
Examiner Name
Attorney Docket Number 082368-003300US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	2004/0082570 A1	04-29-2004	Yoshikawa et al.	
	AB	2004/0146323 A1	06-17-2004	Yoshikawa et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code	Number ⁴	Kind Code ⁵ (if known)				
	AC	WO	01/52825	A2,A3	07-26-2001	Novartis AG		<input type="checkbox"/>
	AD	WO	01/97808	A1	12-27-2001	SmithKline Beecham PLC and SmithKline Beecham Corporation		<input type="checkbox"/>
	AE	WO	02/02560	A2/A3	01-10-2002	Novo Nordisk A/S		<input type="checkbox"/>
	AF	WO	02/068420	A1	09-06-2002	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>
	AG	WO	03/004496	A1	01-16-2003	Novo Nordisk A/S		<input type="checkbox"/>
	AH	WO	03/104229	A1	12-18-2003	Eisai Co., Ltd.		<input checked="" type="checkbox"/>
	AI	WO	2004/050656	A1	06-17-2004	Eisai Co., Ltd.		<input checked="" type="checkbox"/>
	AJ	EP	1 338 595	A2,A3	08-27-2003	Eisai Co., Ltd.		<input type="checkbox"/>

Examiner
Signature

/Charlesworth Rae/

Date
Considered

05/21/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

60669516 v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/